Publications by authors named "A Stuurman"
Background: Although COVID-19 booster vaccination is widely recommended, there is limited long-term, population-level, real-world evidence on the magnitude of improved protection against severe COVID-19 conferred by boosting with monovalent COVID-19 vaccines developed against ancestral SARS-CoV-2, especially in low- or middle-income countries. We present interim results from the first large-scale assessment of the relative vaccine effectiveness (rVE) of first and second booster doses against severe COVID-19 in a low-/middle-income country.
Methods: REFORCO-Brazil is an ongoing, test-negative case-control study (NCT05697705) utilizing Brazil national severe acute respiratory syndrome (SARS) surveillance and vaccination data.
Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.
Lancet Reg Health Eur
August 2023
Background: Vaccine effectiveness (VE) studies with long-term follow-up are needed to understand durability of protection against severe COVID-19 outcomes conferred by primary-series vaccination in individuals not receiving boosters. COVIDRIVE is a European public-private partnership evaluating brand-specific vaccine effectiveness (VE). We report a prespecified interim analysis of primary-series AZD1222 (ChAdOx1 nCoV-19) VE.
View Article and Find Full Text PDFArticle Synopsis
- DRIVE was a European public-private partnership launched in 2017 to estimate influenza vaccine effectiveness (IVE) for public health, conducting studies until the 2021-2022 season.
- In 2021-2022, multiple studies across several European countries involved extensive data collection from over 1,000 general practitioners and several hospitals, utilizing a test-negative design to assess vaccine effectiveness.
- Results showed varying IVE estimates, with notable effectiveness in older adults and children, though sample size limitations impacted precision due to low influenza circulation in Europe that season.
Background: Establishing a large study network to conduct influenza vaccine effectiveness (IVE) studies while collecting appropriate variables to account for potential bias is important; the most relevant variables should be prioritized. We explored the impact of potential confounders on IVE in the DRIVE multi-country network of sites conducting test-negative design (TND) studies.
Methods: We constructed a directed acyclic graph (DAG) to map the relationship between influenza vaccination, medically attended influenza infection, confounders, and other variables.
Article Synopsis
- Effective pandemic preparedness requires a strong, sustainable infrastructure that includes systems for disease surveillance and vaccine monitoring using real-world data.
- Collaboration between the public and private sectors is essential, as demonstrated by initiatives like the DRIVE project that successfully established frameworks for evaluating vaccine effectiveness.
- Ongoing discussions are needed to address the benefits and concerns of Public-Private Partnerships in vaccine monitoring, with a focus on clarifying roles and understanding hesitancy towards these collaborations.